(1S,2R)-2-({[4-({[4-(aminomethyl)cyclohexyl]methyl}amino)-5-nitropyrimidin-2-yl]amino}methyl)cyclohexanol | 737756-44-4

• 分子结构分类: 有机化合物
• 英文名称: (1S,2R)-2-({[4-({[4-(aminomethyl)cyclohexyl]methyl}amino)-5-nitropyrimidin-2-yl]amino}methyl)cyclohexanol
• 英文别名: (1S,2R)-2-[[[4-[[4-(aminomethyl)cyclohexyl]methylamino]-5-nitropyrimidin-2-yl]amino]methyl]cyclohexan-1-ol
• CAS: 737756-44-4
• 化学式: C₁₉H₃₂N₆O₃
• 分子量: 392.501
• InChiKey: FXFDAXMJBXODRE-BOXZVXIZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  142
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• Pyrimidine derivatives useful as inhibitors of PKC-theta
  申请人：Boehringer Ingelheim Pharmaceuticals, Inc.

  公开号：US20040242613A1

  公开（公告）日：2004-12-02

  Disclosed are novel compounds of formula (I): 1 wherein R 1 , R 2 and R 3 are as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本发明涉及一种新颖的化合物，其化学式为（I）：1，其中R1、R2和R3如本文所定义，它们可用作PKC-theta的抑制剂，因此可用于治疗各种通过PKC-theta活性介导或维持的疾病和障碍，包括免疫性障碍和II型糖尿病。本发明还涉及包含这些化合物的药物组合物、使用这些化合物治疗各种疾病和障碍的方法、制备这些化合物的过程以及在这些过程中有用的中间体。
• Stem cell modulation II
  申请人：University of Canberra

  公开号：US10124001B2

  公开（公告）日：2018-11-13

  Disclosed are methods and compositions for modulating cancer stem cells. More particularly, the present invention discloses the use of protein kinase C theta inhibitors (PKC-θ) for inhibiting the growth of PKC-θ-overexpressing cells including cancer stem cells, for enhancing the biological effects of chemotherapeutic drugs or irradiation on cancer cells, for treating cancer, including metastatic cancer and/or for preventing cancer recurrence.

  本发明公开了调节癌症干细胞的方法和组合物。更具体地说，本发明公开了蛋白激酶C theta抑制剂（PKC-θ）的用途，用于抑制包括癌症干细胞在内的PKC-θ过表达细胞的生长，增强化疗药物或照射对癌细胞的生物效应，治疗癌症，包括转移性癌症和/或预防癌症复发。
• 2,4-DIAMINOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA
  申请人：Boehringer Ingelheim Pharmaceuticals Inc.

  公开号：EP1590334B1

  公开（公告）日：2009-08-19
• STEM CELL MODULATION II
  申请人：EpiAxis Therapeutics Pty Ltd

  公开号：EP3046560B1

  公开（公告）日：2021-01-06
• Stem Cell Modulation II
  申请人：UNIVERSITY OF CANBERRA

  公开号：US20160354367A1

  公开（公告）日：2016-12-08

  Disclosed are methods and compositions for modulating cancer stem cells. More particularly, the present invention discloses the use of protein kinase C theta inhibitors (PKC-θ) for inhibiting the growth of PKC-θ-overexpressing cells including cancer stem cells, for enhancing the biological effects of chemotherapeutic drugs or irradiation on cancer cells, for treating cancer, including metastatic cancer and/or for preventing cancer recurrence.